Humanin regulatory status
Current status of Humanin in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Humanin?
Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
- FDA and compounding
- Humanin is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. Without a listing, a 503A pharmacy cannot lawfully compound it as a bulk substance. It is not eligible for 503B outsourcing. Products sold under this name are not lawful for human use.
- WADA
- WADA prohibited
- Access path
- Not legally available: no approved product and no 503A bulks listing.
- Products labeled research use only are not lawful for human use and are not verified for identity or purity.
Full Humanin page: evidence, dosing in the literature, and sources
How has the status of Humanin changed over time?
No dated regulatory event has been recorded for Humanin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Humanin and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026